Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fish and Richardson
Medtronic
Harvard Business School
AstraZeneca
Johnson and Johnson
Healthtrust
Cerilliant
Boehringer Ingelheim

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022360

« Back to Dashboard

NDA 022360 describes NICORETTE, which is a drug marketed by Glaxosmithkline and Glaxosmithkline Cons and is included in four NDAs. It is available from six suppliers. There are three patents protecting this drug and two Paragraph IV challenges. Additional details are available on the NICORETTE profile page.

The generic ingredient in NICORETTE is nicotine polacrilex. There are thirty drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
Summary for 022360
Tradename:NICORETTE
Applicant:Glaxosmithkline Cons
Ingredient:nicotine polacrilex
Patents:2
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022360
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360 NDA GlaxoSmithKline Consumer Healthcare Holdings (US) LLC 0135-0508 N 0135-0508-02
NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360 NDA GlaxoSmithKline Consumer Healthcare Holdings (US) LLC 0135-0508 N 0135-0508-03

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:TROCHE/LOZENGE;ORALStrengthEQ 2MG BASE
Approval Date:May 18, 2009TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 14, 2029Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Apr 30, 2029Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:TROCHE/LOZENGE;ORALStrengthEQ 4MG BASE
Approval Date:May 18, 2009TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 14, 2029Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022360

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-001 May 18, 2009 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-002 May 18, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Boehringer Ingelheim
Federal Trade Commission
Julphar
Colorcon
Fuji
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.